(19)
(11) EP 2 561 887 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
21.12.2016 Bulletin 2016/51

(45) Mention of the grant of the patent:
13.01.2016 Bulletin 2016/02

(21) Application number: 12183770.2

(22) Date of filing: 14.01.2004
(51) International Patent Classification (IPC): 
A61K 38/17(2006.01)
A61K 45/06(2006.01)
A61P 35/00(2006.01)
A61K 31/4745(2006.01)
A61K 33/24(2006.01)
 A61K 38/39(2006.01)
A61K 48/00(2006.01)
A61K 31/513(2006.01)
A61K 31/7048(2006.01)

(54)

Cancer therapy sensitizer

Sensibilisator für Krebstherapie

Sensibilisateur de thérapie anticancéreuse

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

(30) Priority: 14.01.2003 US 440009 P

(43) Date of publication of application:
27.02.2013 Bulletin 2013/09

(62) Application number of the earlier application in accordance with Art. 76 EPC:
04702173.8 / 1594433

(73) Proprietor: Dana-Farber Cancer Institute, Inc.
Boston, MA 02115-5450 (US)

(72) Inventors:
  • Tai, Isabelle, T.
    Vancouver, British Columbia V6Z 3A9 (CA)
  • Chen, Lan Bo
    Lexington, MA 02420 (US)

(74) Representative: D Young & Co LLP 
120 Holborn
London EC1N 2DY
London EC1N 2DY (GB)


(56) References cited: : 
   
  • STEIN U ET AL: "Reversal of Multidrug Resistance by Transduction of Cytokine Genes into Human Colon Carcinoma Cells", JOURNAL OF THE NATIONAL CANCER INSTITUTE. MONOGRAPHS, SERVICE, NATIONAL INSTITUTES OF HEALTH, WASHINGTON, DC, vol. 88, no. 19, 2 October 1996 (1996-10-02), pages 1383-1392, XP002493063, ISSN: 1052-6773
  • GARY K YIU ET AL: "SPARC (SECRETED PROTEIN ACIDIC AND RICH IN CYSTEINE) INDUCES APOPTOSIS IN OVARIAN CANCER CELLS", AMERICAN JOURNAL OF PATHOLOGY; [10640], AMERICAN SOCIETY FOR INVESTIGATIVE PATHOLOGY, US, vol. 159, no. 2, 1 August 2001 (2001-08-01), pages 609-622, XP002983766, ISSN: 0002-9440
  • CHLENSKI A ET AL: "SPARC IS A KEY SCHWANNIAN-DERIVED INHIBITOR CONTROLLING NEUROBLASTOMA TUMOR ANGIOGENESIS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 62, 15 December 2002 (2002-12-15), pages 7357-7363, XP002986916, ISSN: 0008-5472
  • DHANESUAN N ET AL: "Doxycycline-inducible expression of SPARC/Osteonectin/BM40 in MDA-MB-231 human breast cancer cells results in growth inhibition", BREAST CANCER RESEARCH, CURRENT SCIENCE, LONDON, GB, vol. 75, no. 1, 1 September 2002 (2002-09-01), pages 73-85, XP002493062, ISSN: 1465-5411, DOI: 10.1023/A:1016536725958
  • TAI ISABELLA T ET AL: "Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 115, no. 6, 1 June 2005 (2005-06-01), pages 1492-1502, XP002488747, ISSN: 0021-9738, DOI: 10.1172/JCI23002
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).